Carolyn Ng

Carolyn Ng, Ph.D., is Managing Director at Vertex Ventures HC. At Vertex Ventures HC, Carolyn is responsible for driving venture investments across biotechnology, medical devices, and health technology fields. Carolyn currently serves on the Board of Directors for Epirium Bio, Boundless Bio, Obsidian Therapeutics, Twentyeight-Seven Therapeutics, and Nuvaira. She was previously on the board of Bicycle Therapeutics (NASDAQ: BCYC), and a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for $430M) and Earlens. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for $458 M). Working across the U.S., Europe, and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development,
and syndication.
Speaking In
11:00 AM - 12:00 PM (EST)
Tuesday, February 16
Frequently altered driver genes in cancer, such as RAS, TP53 and MYC, are attractive targets for…